Rallybio Stock Soars: Big News for 2025!

miércoles, 4 de junio de 2025, 3:24 pm ET1 min de lectura
RLYB--
Rallybio Corporation surged 24.83% intraday, as the company plans to initiate confirmatory pharmacokinetics and pharmacodynamics studies for RLYB116 in the second quarter of 2025, with data expected to be released in the third and fourth quarters of 2025. The company's market response was notable on Wednesday's trading, with the stock price rising 35.87% to $0.40, resulting in a market capitalization of $16.6 million.

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios